Financial News

Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars

Products You May Like

  • The shift introduced by Quebec will observe an analogous strategy to insurance policies launched in British Columbia, Alberta and not too long ago in New Brunswick to transition sufferers who use a reference biologic to a biosimilar. This may contribute to substantial annual financial savings that may be reinvested in healthcare and modern new medication.
  • The transition will happen beneath the supervision of the attending physicians and sufferers will proceed receiving secure and efficient remedy. Sandoz Canada has a portfolio of six biosimilars (Omnitrope, Rixymio, Erelzi, Hyrimoz, Ziextenzo and Inclunox).
  • Sandoz Canada is dedicated to supporting sufferers, their healthcare professionals and the Quebec authorities all through the transition interval with high quality biosimilar medicines, medical groups, doctor and pharmacist advocacy groups, in addition to confirmed affected person assist applications.

BOUCHERVILLE, Quebec, Might 18, 2021 (GLOBE NEWSWIRE) — Sandoz Canada, a frontrunner in generic prescription drugs and biosimilars, welcomes the Quebec Authorities’s shift in the direction of biosimilars. According to the government’s announcement, this transition will generate annual financial savings of greater than $100 for the general public drug insurance coverage plan and its insured events. These financial savings will likely be reinvested within the healthcare system to enhance entry to modern drug therapies, specifically.

Quebec is following the biosimilar transition insurance policies applied by British Columbia and Alberta in 2019 and, extra not too long ago, New Brunswick in 2021. With this announcement, the provinces which have adopted and applied such a coverage now make it attainable for nearly half of the Canadian inhabitants to learn from it1. Beneath the Quebec initiative, the province will ultimately cowl solely biosimilar medication on formularies, with some exceptions, and can transition sufferers who use the reference biologic medication to the listed biosimilar by April 12, 2022, beneath the supervision of their attending physicians.

“At Sandoz Canada, we’re happy to see that Quebec is adopting a change coverage already initiated by different provinces and is transferring in the direction of biosimilars. We’re able to assist the federal government, physicians, pharmacists and all healthcare professionals with our six high quality biosimilars, whereas serving to to generate vital financial savings for the healthcare system,” stated Michel Robidoux, President and Normal Supervisor, Sandoz Canada. “With COVID-19 inserting our healthcare system beneath main funds constraints, biosimilar transition insurance policies are a chance to contribute to the sustainability of well being system financing and supply funding for brand new improvements,” he added.

“The federal government has said its intention to interact in discussions with key healthcare companions, and Sandoz intends to actively cooperate in these discussions. We wish to share our expertise with the Ministry in an effort to present sufferers with the very best high quality of care. It’ll even be a chance to make clear sure particulars of the shift in the direction of biosimilars, specifically with the new regulation (section 80.2) coming into impact as a part of the Act respecting prescription drug insurance coverage,” stated Karine Matteau, Vice President, Bio-Generic Hospital/Doctor channel and Head of Biosimilars at Sandoz Canada. “Sandoz is absolutely dedicated to supporting sufferers and their healthcare staff throughout this transition interval and past by means of our training initiatives and our affected person assist applications. We now have arrange a web site for Canadians,, which incorporates a wealth of data and sources associated to biosimilars,” she added.

About Biosimilars

A biosimilar is a biologic medication that has demonstrated it’s extremely comparable and has no clinically significant variations in efficacy and security in comparison with the reference biologic already approved on the market.2 Biosimilars might change into commercially accessible following the expiry of patents and knowledge safety intervals of the reference biologic medication.

The Patented Medicines Pricing Evaluation Board has estimated that non-public and public drug plans throughout Canada may save from CA$294 million to CA$1.136 billion by 2021 for established biosimilars3 accessible in Canada for a minimum of two years, and from CA$222 million to CA$447 million by 20234 for brand new biosimilars that not too long ago entered the Canadian market.

For additional data on biosimilars in Canada, go to, which goals to assist and educate sufferers, healthcare professionals and Canadians by offering coverage updates from public drug plans, in addition to evidence-based data and sources from Canadian, worldwide analysis and medical communities, and affected person organizations representing Canadians residing with continual illnesses who take biologic medicines. As well as, the positioning additionally presents the positions of organizations that signify Canadian sufferers with continual illnesses who take biologic medication.

Since 2009, Well being Canada has approved 36 biosimilars of reference biologics current on the Canadian market5 and Sandoz Canada has six of them marketed within the nation (Omnitrope, Erelzi, Ziextenzo, Riximyo, Hyrimoz and Inclunox).

About transitioning

Within the context of biosimilar use, Well being Canada “considers switching between approved merchandise to check with a change from routine use of 1 particular product to routine use of one other particular product. Sufferers and healthcare suppliers can trust that biosimilars are efficient and secure for every of their approved indications. No variations are anticipated in efficacy and security following a change in routine use between a biosimilar and its reference biologic drug in a licensed indication.”6

About Sandoz Canada

Sandoz Worldwide GmbH is a world chief in generics and biosimilars and a division of the Swiss multinational Novartis.

Sandoz Canada is a pioneer, a frontrunner and trusted provider of high quality generics and biosimilars with over 65 million prescriptions per yr, based mostly on many years of world expertise and capabilities within the growth, manufacturing and commercialization of its merchandise. Sandoz launched the primary biosimilar in Europe in 2006 and within the Canadian market in 2009.

Comply with us on LinkedIn:

For interview requests, please contact Paule Pelletier (see contact data under).

Paule Pelletier
Sandoz Canada Inc.
+1-514-702-7699 /


1 Statistics Canada, Inhabitants Estimates, Quarterly,
2 Well being Canada Biosimilars Reality Sheet: Biosimilars Defined.
3 Authorities of Canada,
Biologics in Canada. Half 2:
Potential financial savings related to biosimilars in Canada.
4 Ibid
5 Discover of Compliance Search, Well being Canada
6 Well being Canada Reality Sheet on Biosimilars: Switching

Primary Logo

Products You May Like